Form 8-K - Current report:
SEC Accession No. 0001730430-26-000017
Filing Date
2026-04-28
Accepted
2026-04-28 07:32:20
Documents
13
Period of Report
2026-04-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K knsa-20260428x8k.htm   iXBRL 8-K 41257
2 EX-99.1 knsa-20260428xex99d1.htm EX-99.1 135691
3 GRAPHIC knsa-20260428xex99d1001.jpg GRAPHIC 9790
  Complete submission text file 0001730430-26-000017.txt   312022

Data Files

Seq Description Document Type Size
4 EX-101.SCH knsa-20260428.xsd EX-101.SCH 2666
5 EX-101.LAB knsa-20260428_lab.xml EX-101.LAB 15215
6 EX-101.PRE knsa-20260428_pre.xml EX-101.PRE 9627
16 EXTRACTED XBRL INSTANCE DOCUMENT knsa-20260428x8k_htm.xml XML 4688
Mailing Address 105 PICCADILLY, SECOND FLOOR LONDON United Kingdom W1J 7NJ
Business Address 105 PICCADILLY, SECOND FLOOR LONDON United Kingdom W1J 7NJ 7814319100
Kiniksa Pharmaceuticals International, plc (Filer) CIK: 0001730430 (see all company filings)

EIN.: 981795578 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38492 | Film No.: 26903152
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)